Nebenwirkungen · Symtuza
Symtuza 800 mg/150 mg/200 mg/10 mg film-coated tablets Symtuza 675 mg/150 mg/200 mg/10 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 22
HOS-138534 · Präparat HOS-098200
Paediatric population The safety of Symtuza (as an FDC formulation) has not been investigated in paediatric patients. However, the safety of its components was evaluated in adolescents aged 12 to less than 18 years and weighing at least 40 kg through the clinical study TMC114-C230 (N = 12) for darunavir with ritonavir and clinical study GS-US-292-0106 (N = 50) for an FDC containing elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-16T11:21:00Z · SHA-256 542f840b29cc7afaff9940b20511550e8d35031b33d95efd774fd49f70f7819d · Passage 46153fd8891e0af8929f5c9b51f60d585c721032857730485d710411c3df1a41 · Zeichen 9747–10198 im Abschnitt